Nachrichten zur Gilead Sciences Inc. Aktie

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

Gilead Sciences (GILD) concluded the recent trading session at $110.99, signifying a -2.36% move from its prior days close.…

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.…

Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More

…

Gilead Sciences Aktie bleibt ein Kauf! Morgan Stanley sieht stabile Pipeline

Bad Marienberg (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse: Morgan Stanley bestätigt Kursziel 143 USDDie Analysten von Morgan Stanley haben am 21. September…

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior days close.…

Gilead Sciences Q2: The New Drug That Could Change Everything

…

Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the…

Gilead posts flat quarterly profit, raises full-year outlook

Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial outlook due largely…

Gilead Sciences Aktie: 140 oder 96 USD? Ziele und Ratings der Analysten vor Q2 2025 Zahlen auf einen Blick - Aktiennews

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the…

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year

On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock(NASDAQ:SRRK) in an…

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its…

Gilead Sciences CFO Dickinson sells $277k in stock By Investing.com

Gilead Sciences CFO Dickinson sells $277k in stock…

Heres Why Gilead Sciences (GILD) Fell More Than Broader Market

Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.…

Heres Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading…

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth…

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.…

Gilead Sciences: A Mixed Bag of Opportunities and Risks

Explore the exciting world of Gilead Sciences (NASDAQ: GILD) with our expert analysts in this Motley Fool Scoreboard episode. Check…

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.…

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware…

Gilead Sciences (GILD) Stock Moves -1.18%: What You Should Know

Gilead Sciences (GILD) concluded the recent trading session at $105.93, signifying a -1.18% move from its prior days close.…

Gilead partners with Kymera to develop novel cancer therapy

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on...…

Gilead Sciences Aktie: HIV-Hoffnung Yeztugo im Fokus - Outperform-Rating bekräftigt

New York (www.aktiencheck.de) - Gilead-Aktienanalyse von Oppenheimer: Die Analysten von Oppenheimer haben das Rating "outperform" für die Aktie von Gilead Sciences…

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences Aktie: "Großer Sieg! durch Yeztugo-Zulassung!

Toronto (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von BMO Capital Markets: Wenn es nach den Analysten von BMO Capital Marktes gehe, dann habe…

Gilead Sciences Aktie: Deutlicher Optimismus!

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Mizuho Securities USA: Nach der FDA-Zulassung des injizierbaren HIV-1-Capsid-Hemmers Yeztugo (Lenacapavir) habe das Analysehaus…

Gilead Sciences Aktie: Startschuss für Yeztugo - "Erwarteter Turbo“ für die Aktie!

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Morgan Stanley: Die Genehmigung durch die US-Arzneimittelbehörde FDA könnte als wichtiger Meilenstein für Gilead…

Gilead Sciences: Zulassung für HIV-Prophylaxe mit Gamechanger-Potenzial - News verpuffen

Gilead Sciences hat die vom Markt erwartete Marktzulassung für seine neuartige HIV-Präventionstherapie Lenacapavir von der FDA erhalten. Doch wie gewonnen,…

Gilead Sciences: Zulassung für HIV-Prophylaxe mit Gamechanger-Potenzial – News verpuffen

Gilead Sciences hat die vom Markt erwartete Marktzulassung für seine neuartige HIV-Präventionstherapie Lenacapavir von der FDA erhalten. Doch wie gewonnen,…

Gilead Sciences: Zulassung für HIV-Prophylaxe mit Gamechanger-Potenzial – News verpuffen

Gilead Sciences hat die vom Markt erwartete Marktzulassung für seine neuartige HIV-Präventionstherapie Lenacapavir von der FDA erhalten. Doch wie gewonnen,…

Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS)’s twice-yearly injectable HIV prevention drug lenacapavir is on track for a solid launch after being…

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

…

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware…

Why Gilead Scinces Stock Tumbled on Tuesday

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took…

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

…

Gilead Sciences shares hit after HIV studies placed on hold by FDA By Investing.com

Gilead Sciences shares hit after HIV studies placed on hold by FDA…

Gilead shares fall after FDA places clinical hold on HIV treatment trials

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) dropped up to 4% on Tuesday following an announcement that the US Food and Drug…

Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)

…

Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However, we recommend…

Gilead Sciences, Inc. (GILD) Bernstein 41st Annual Strategic Decisions Conference (Transcript)

…

Gilead Sciences Best Days May Be Ahead - Heres Why

…

Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)

…

Heres Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a…

Gilead Sciences Aktie: 140 oder 93 USD? Kursziele und Ratings der Analysten nach Q1-Zahlen auf einen Blick - Aktiennews

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

Disney, Gilead Sciences, Eaton and Maui Land & Pineapple are included in this Analyst Blog.…

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but…

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

Todays Research Daily features new research reports on 16 major stocks, including The Walt Disney Co. (DIS), Gilead Sciences, Inc.…

Gilead announces $11 billion in new investments in US

Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned…